Compare TRUP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | ANAB |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2014 | 2017 |
| Metric | TRUP | ANAB |
|---|---|---|
| Price | $36.20 | $45.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $54.00 | ★ $58.09 |
| AVG Volume (30 Days) | 368.7K | ★ 501.4K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,399,759,000.00 | $169,467,000.00 |
| Revenue This Year | $14.10 | $135.45 |
| Revenue Next Year | $9.54 | N/A |
| P/E Ratio | $99.75 | ★ N/A |
| Revenue Growth | 12.50 | ★ 196.42 |
| 52 Week Low | $31.00 | $12.21 |
| 52 Week High | $57.89 | $52.47 |
| Indicator | TRUP | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 52.09 |
| Support Level | $34.46 | $42.00 |
| Resistance Level | $36.60 | $47.36 |
| Average True Range (ATR) | 1.10 | 2.45 |
| MACD | -0.13 | -0.84 |
| Stochastic Oscillator | 39.32 | 35.20 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).